Atul Saran

Senior Vice President, Corporate Development and Ventures, MedImmune Ventures, Inc.

Atul Saran assumed the role of Senior Vice President, Corporate Development and Ventures at MedImmune in 2011. He has responsibility for MedImmune’s corporate development activities, primarily including worldwide biologics and vaccines strategic business development transactions for the AstraZeneca Group, as well as responsibility for new MedImmune corporate ventures and oversight of MedImmune Ventures.

Mr. Saran joined MedImmune in 2003 as the company’s first in-house corporate and securities lawyer and worked with the general counsel to develop a strategically focused legal department, in which he held positions of increasing seniority, most recently as vice president and deputy general counsel, with responsibility for managing the legal department (other than the intellectual property team). During his tenure in the legal department, Mr. Saran helped structure and complete critical initiatives and transactions for the organization including the production of H1N1 vaccine for the U.S. government in 2009, the acquisition of MedImmune by AstraZeneca in 2007, the acquisition and divestiture of key pipeline technologies and various structured finance transactions. Mr. Saran also worked with the management team to establish the governance and operational framework for MedImmune Ventures and execution of its subsequent investment strategy. Mr. Saran came to MedImmune from Hogan & Hartson, where he was an associate attorney in the Private Equity/Emerging Business Practice Group.

Mr. Saran graduated summa cum laude from the University of Illinois College of Law, and received his bachelor’s degree in biological sciences from Stanford University. He also successfully completed two years of medical school at the University of Illinois College of Medicine and Step 1 of the United States Medical Licensing Examination.